Scisparc Ltd
SPRC1.460USD
-0.060-3.95%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
780.52KMarket Cap
LossP/E TTM
More Details of Scisparc Ltd Company
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Scisparc Ltd Info
Ticker SymbolSPRC
Company nameScisparc Ltd
IPO dateDec 22, 2021
CEOWeiss (Amitay)
Number of employees2
Security typeOrdinary Share
Fiscal year-endDec 22
Address20 Raul Wallenberg Street, Tower A
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code6971916
Phone97236103100
Websitehttps://scisparc.com/
Ticker SymbolSPRC
IPO dateDec 22, 2021
CEOWeiss (Amitay)
Company Executives of Scisparc Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Itschak Shrem
Mr. Itschak Shrem
Chairman of the Board
Chairman of the Board
16.00
+128.57%
Mr. Amitay Weiss
Mr. Amitay Weiss
Chief Executive Officer, Director
Chief Executive Officer, Director
1.00
--
Prof. Ari Shamiss, M.D.
Prof. Ari Shamiss, M.D.
Independent Director
Independent Director
--
--
Mr. Alon Dayan
Mr. Alon Dayan
Independent Director
Independent Director
--
--
Dr. Adi Zuloff-Shani
Dr. Adi Zuloff-Shani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Amnon Shay
Mr. Amnon Shay
Independent Director
Independent Director
--
--
Mr. Moshe Revach
Mr. Moshe Revach
Director
Director
--
--
Mr. Lior Vider
Mr. Lior Vider
Independent Director
Independent Director
--
--
Ms. Liat Sidi
Ms. Liat Sidi
Director
Director
--
--
Mr. Oz Adler, CPA
Mr. Oz Adler, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Itschak Shrem
Mr. Itschak Shrem
Chairman of the Board
Chairman of the Board
16.00
+128.57%
Mr. Amitay Weiss
Mr. Amitay Weiss
Chief Executive Officer, Director
Chief Executive Officer, Director
1.00
--
Prof. Ari Shamiss, M.D.
Prof. Ari Shamiss, M.D.
Independent Director
Independent Director
--
--
Mr. Alon Dayan
Mr. Alon Dayan
Independent Director
Independent Director
--
--
Dr. Adi Zuloff-Shani
Dr. Adi Zuloff-Shani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Amnon Shay
Mr. Amnon Shay
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 15
Updated: Mon, Dec 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ronen (Fatal)
8.77%
Eli (Zamir)
8.77%
Daniel (Nissim)
8.77%
UBS Switzerland AG
0.16%
BofA Global Research (US)
0.04%
Other
73.49%
Shareholders
Shareholders
Proportion
Ronen (Fatal)
8.77%
Eli (Zamir)
8.77%
Daniel (Nissim)
8.77%
UBS Switzerland AG
0.16%
BofA Global Research (US)
0.04%
Other
73.49%
Shareholder Types
Shareholders
Proportion
Individual Investor
26.30%
Bank and Trust
0.16%
Investment Advisor/Hedge Fund
0.08%
Research Firm
0.04%
Investment Advisor
0.03%
Other
73.38%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
15
9.03K
0.56%
+2.09K
2025Q2
20
5.89K
1.10%
-4.32K
2025Q1
22
123.94K
1.13%
-90.52K
2024Q4
22
186.52K
1.22%
-6.68K
2024Q3
20
179.36K
1.73%
+90.02K
2024Q2
22
138.03K
12.19%
+104.31K
2024Q1
20
67.89K
2.29%
+37.60K
2023Q4
19
11.96K
4.65%
-10.95K
2023Q3
23
5.71K
4.48%
-17.08K
2023Q2
22
12.21K
6.80%
-11.05K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
UBS Switzerland AG
--
0%
-283.00
-100.00%
Mar 31, 2025
BofA Global Research (US)
2.00
0%
--
--
Jun 30, 2025
Shrem (Itschak)
16.00
0%
+9.00
+128.57%
Apr 23, 2025
SBI Securities Co., Ltd.
18.00
0%
+4.00
+28.57%
Jun 30, 2025
UBS Financial Services, Inc.
3.31K
0.2%
+3.31K
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
1.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 21, 2025
Merger
21→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Date
Type
Ratio
May 21, 2025
Merger
21→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
FAQs
Who are the top five shareholders of Scisparc Ltd?
The top five shareholders of Scisparc Ltd are:
UBS Switzerland AG holds 0.00 shares, accounting for 0.00% of the total shares.
BofA Global Research (US) holds 2.00 shares, accounting for 0.00% of the total shares.
Shrem (Itschak) holds 16.00 shares, accounting for 0.00% of the total shares.
SBI Securities Co., Ltd. holds 18.00 shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 3.31K shares, accounting for 0.20% of the total shares.
UBS Switzerland AG holds 0.00 shares, accounting for 0.00% of the total shares.
BofA Global Research (US) holds 2.00 shares, accounting for 0.00% of the total shares.
Shrem (Itschak) holds 16.00 shares, accounting for 0.00% of the total shares.
SBI Securities Co., Ltd. holds 18.00 shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 3.31K shares, accounting for 0.20% of the total shares.
What are the top three shareholder types of Scisparc Ltd?
The top three shareholder types of Scisparc Ltd are:
Ronen (Fatal)
Eli (Zamir)
Daniel (Nissim)
Ronen (Fatal)
Eli (Zamir)
Daniel (Nissim)
How many institutions hold shares of Scisparc Ltd (SPRC)?
As of 2025Q3, 15 institutions hold shares of Scisparc Ltd, with a combined market value of approximately 9.03K, accounting for 0.56% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.54%.
What is the biggest source of revenue for Scisparc Ltd?
In --, the -- business generated the highest revenue for Scisparc Ltd, amounting to -- and accounting for --% of total revenue.
